Trial Profile
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Tesetaxel (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONTESSA
- Sponsors Odonate Therapeutics
- 26 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database
- 09 Jul 2021 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.